The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Biomarkers for Alzheimer’s Disease
Abstract
Alzheimer´s disease (AD) and related forms of dementia are increasingly affecting the aging population throughout the world, at an alarming rate. The World Alzheimer´s Report indicates a prevalence of 46.8 million people affected by AD worldwide. As population ages, this number is projected to triple by 2050 unless effective interventions are developed and implemented. Urgent efforts are required for an early detection of this disease. The ultimate goal is the identification of viable targets for the development of molecular markers and validation of their use for early diagnosis of AD that may improve treatment and the disease outcome in patients. The diagnosis of AD has been difficult to resolve since approaches for early and accurate detection and follow-up of AD patients at the clinical level have been reported only recently. Some proposed AD biomarkers include the detection of pathophysiological processes in the brain in vivo with new imaging techniques and novel PET ligands, and the determination of pathogenic proteins in cerebrospinal fluid showing anomalous levels of hyperphosphorylated tau and low Aβ peptide. These biomarkers have been increasingly accepted by AD diagnostic criteria and are important tools for the design of clinical trials, but difficulties in accessibility to costly and invasive procedures have not been completely addressed in clinical settings. New biomarkers are currently being developed to allow determinations of multiple pathological processes including neuroinflammation, synaptic dysfunction, metabolic impairment, protein aggregation and neurodegeneration. Highly specific and sensitive blood biomarkers, using less-invasive procedures to detect AD, are derived from the discoveries of peripheric tau oligomers and amyloid variants in human plasma and platelets. We have also developed a blood tau biomarker that correlates with a cognitive decline and also with neuroimaging determinations of brain atrophy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tau positron emission tomography (tau PET), neurofilament light, and neurogranin are the new biomarkers that are increasingly used by clinical trials.40”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [40]
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Neuroinflammation in Parkinson's disease
Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657
Flagged first, then by citations
Research works printed but not linked: 17
- Alzheimar A. Psychiatr Psych gericht Med, Über eine eigenartige Erkrankung der Hirnrinde.,, , 64,, 146-8,1907
- Maccioni RB, Perry G. Current Hypotheses and Research Milestones in Alzheimer's Disease New York: Springer Science+Bussiness Media, LLC;, ,, , 17,, 3-241,(2009)
- . Alzheimer's , Association As 2018 Alzheimer’s disease facts and figures.,, , 14,, 367-429,(2018)
- Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L. J Med Assoc, Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer’s disease (AD) and other dementia at Siriraj Hospital, Thailand.,, , 94,, S77-S83,(2011)
- Sohma H, Kokai Y. Update on Dementia: InTech, ,, (2016), 8,, 67-83,
- McGhee DJ, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE. PLoS One, A systematic review of biomarkers for disease progression in Alzheimer’s disease.,, , 9,, 1809-,(2014)
- Sjodin S, Hansson O, Ohrfelt A, Brinkmalm G, Zetterberg H, Brinkmalm A. Proteom Clin App, Mass spectrometric analysis of cerebrospinal fluid ubiquitin in Alzheimer's disease and Parkinsonian disorders.,, , 11,, 340-,(2017)
- Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. The Cochrane Database Syst Rev, CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI).,, , 3,, 454-,(2017)
- Rojo L, Sjoberg MK, Hernandez P, Zambrano C, Maccioni RB. J Biomed Biotechnol, Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer’s disease.,, , 2006,, 73976-,(2006)
- Borroni B, Colciaghi F, Pastorino L, Pettenati C, Cottini E, Rozzini L. Arch Neurol, Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.,, , 58,, 442-446,(2001)
- Martinez B, Peplow PV. Neural Regen Res, MicroRNAs as diagnostic and therapeutic tools for Alzheimer’s disease: advances and limitations.,, , 14,, 242-255,(2019)
- Chang WS, Wang YH, Zhu XT, Wu CJ. Med Sci, Genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease.,, , 23,, 2721-2731,(2017)
- Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias GA, Maccioni RB. Front Cell Neurosci, Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches.,, , 8,, 112-,(2014)
- Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J, Campos-Pena V. Front Integr Nuerosci, Inflammatory process in Alzheimer’s Disease.,, , 7,, 59-,(2013)
- Nuzzo D, Picone P, Caruana L, Vasto S, Barera A, Caruso C. Inflammation, Inflammatory mediators as biomarkers in brain disorders.,, , 69,, 639-648,(2014)
- Mosconi L. Clin Trans Imag, Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies.,, , 1,, 1419-,(2013)
- Perani D, Schillaci O, Padovani A, Nobili FM, Iaccarino L, Della Rosa PA. BioMed Res Int, A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.,, , 2014,, 1419-,(2014)
Cited by
Sorted by citations
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309
Novel Nutraceutical Compounds in Alzheimer Prevention
Maccioni, R. B., Calfío, C., González, A., & Lüttges, V. (2022) · Biomolecules · doi:10.3390/biom12020249 · Cited by 45
Self-citation
Metadata
- Authors
- Guzman-Martinez, L., Maccioni, R. B., Farías, G. A., Fuentes, P., & Navarrete, L. P.
- Affiliations
- Faculty of Sciences, University of Chile, Santiago, Chile
- University of Chile (CL)
- Clinical Hospital, University of Chile, Santiago, Chile
- Hospital Clínico de la Universidad de Chile (CL)
- Corresponding author
- Maccioni, Ricardo B.
- Venue
- Current Alzheimer Research
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2019-07-23
- Volume
- 16
- Issue
- 6
- Pages
- 518-528
- ISSN
- 1567-2050 (ISSN-L)
- OpenAlex
- W3098965555
- Cited by
- 87
- References
- 101
- Citations by year
- 2026: 1 · 2025: 13 · 2024: 17 · 2023: 18 · 2022: 20 · 2021: 4 · 2020: 12 · 2019: 2
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Alzheimer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, biomarkers, early diagnosis, cerebrospinal fluid, hyperphosphorylated tau, amyloid-beta, positron emission tomography, blood biomarkers, neuroinflammation, synaptic dysfunction, neurodegeneration, brain atrophy, cognitive decline
- MeSH terms
- Alzheimer Disease, Humans, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
